Radiopharmaceuticals Based on Polyaminophosphonic Acids Labeled with α−, β−, and γ-Emitting Radionuclides (Review)

Tishchenko, V. K.; Петриев, В. М.; Скворцов, В. Г.

doi:10.1007/s11094-015-1299-4

Cited by 8 publications

(5 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, when irradiated under medium to high neutron flux conditions, appreciable amounts of 171 Tm are formed which will remain as contaminants long after the desired 170 Tm has decayed due to its much longer half-life (Sahiralamkhan et al 2016 ). This poses significant clinical translation issues for formulations of 170 Tm due to the contaminant 171 Tm exhibiting vastly different β − -decay and γ-emission properties, with a maximum β − -particle energy of only 97 keV (approximately 10% of 170 Tm β − -particle energy) and a very low abundance γ-emission energy (66.7 keV, 0.16%) (Sahiralamkhan et al 2016 ; Kajan et al 2018 ; Tishchenko et al 2015 ). Furthermore, due to its identical chemical nature, 171 Tm cannot be separated from the desired 170 Tm using traditional chemical means such as chromatography or extraction methodologies and consequently the specific activity and radiopurity of the final formulation are adversely affected.…”

Section: Thulium: 170 Tmmentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

Section: Thulium: 170 Tmmentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…Therefore, for chemical elements of interest to MEDICIS [1], laser resonance ionization spectroscopy studies were undertaken to define laser ionization schemes, suitable for the emission range of titanium:sapphire lasers. This work is focused on rare-earth elements, because many medically relevant isotopes, being promising for the theranostics approach [10], are found within this group. Several lanthanides, such as Dy, Ho, and Yb, were already investigated [11], [12].…”

Section: Laser Resonance Ionization Spectroscopymentioning

confidence: 99%

MELISSA: Laser ion source setup at CERN-MEDICIS facility. Blueprint

Gadelshin

Barozier

Cocolios

et al. 2020

Nuclear Instruments and Methods in Physics Research Section B:

View full text Add to dashboard Cite

The Resonance Ionization Laser Ion Source (RILIS) has become an essential feature of many radioactive ion beam facilities worldwide since it offers an unmatched combination of efficiency and selectivity in the production of ion beams of many different chemical elements. In 2019, the laser ion source setup MELISSA is going to be established at the CERN-MEDICIS facility, based on the experience of the workgroup LARISSA of the University Mainz and CERN ISOLDE RILIS team. The purpose is to enhance the capability of the radioactive ion beam supply for end users by optimizing the yield and the purity of the final product. In this article, the blueprint of the laser ion source, as well as the key aspects of its development and operation are presented.

show abstract

“…A wide range of radionuclides have been investigated with such ligand systems, many of which ( 99m Tc, 68 Ga, 227 Th, 228 Ac, 212 Bi, 188 Re) are beyond the realm of this current review, but are discussed in the context of (poly)aminophosphonic acids elsewhere. 28 Specific review articles have also focused upon the targeted treatment of bone metastases using phosphonate-based ligands 29 and a broad range of radionuclides. Although not an aminophosphonic acid, the structurally simplest biphosphonic acid derivative is pyrophosphonic acid (Fig.…”

Section: Complexes Based On (Poly)aminophosphonic Acidsmentioning

confidence: 99%